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Abstract
Introduction: Though remission is currently a treatment goal in patients with rheumatoid arthritis (RA), the number of 
patients who achieve and sustain remission in daily practice is still small. It is suggested that early remission will be 
associated with sustainability of remission. The aim was to study the association between time-to-remission and 
sustainability of remission in a cohort of early RA patients treated according to daily practice.
Methods: For this study, three-year follow-up data were used from the Nijmegen RA Inception Cohort of patients 
included between 1985 and 2005 (N = 753). Patients were included upon diagnosis (ACR criteria), were systematically 
evaluated at three-monthly visits and treated according to daily practice. Remission was defined according to the 
Disease Activity Score (DAS) <1.6 and the ACR remission criteria. Remission of at least 6 months duration was regarded 
as sustained remission. Predictors for time-to-remission were identified by Cox-regression analyses. The relation 
between time-to-remission and sustained remission was analyzed using longitudinal binary regression.
Results: N = 398 (52%) patients achieved remission with a median time-to-remission of 12 months. Male gender, 
younger age and low DAS at baseline were predictive to reach remission rapidly. There were n = 142 (36%) patients 
experiencing sustained remission, which was determined by a shorter time-to-remission only. The relationship 
between time-to-remission and sustained remission was described by a significant odds ratio (1.11) (1.10 to 1.12-95% 
CI) that was constant over the whole period 1985 to 2005. Results obtained with the ACR remission criteria were similar.
Conclusions: A shorter time-to-remission is related to sustainability of remission, supporting striving for early 
remission in patients with RA.
Introduction
Expectations considering the treatment effect of rheuma-
toid arthritis (RA) have changed and aiming for clinical
remission is currently regarded as an appropriate treat-
ment goal in patients with early RA[1]. However, the
number of patients who achieve remission in routine care
is small and only a minority of these patients reach sus-
tained remission [2,3]. Rather than complete remission, it
is a near-remission disease state that currently is an
achievable treatment goal in daily practice. Forthcoming
treatment approaches will make the remission aim more
realistic.
Starting treatment as early as possible after the diagno-
sis of RA is essential to provide the best clinical out-
come[4]. Moreover, starting methotrexate (MTX) in
combination with corticosteroids has been shown to be
very successful in aiming for remission; 30 to 40% of early
RA patients will experience a sustained good clinical
response to MTX monotherapy [5,6]. In case MTX ther-
apy fails, biological therapy should be added to disease-
modifying anti-rheumatic drug (DMARD) therapy [5-8].
Additionally to this add-on strategy, applying tight con-
trol increases the ability to induce remission in early
RA[9]. Tight control includes regular adaptations of
treatment guided by the level of disease activity, i.e.
remission[10]. Application of tight control may even be
more important than the initial treatment given [5,9].
Following the concept of 'a window of opportunity'-
successful disease course modification Is determined by
aggressive treatment early in the disease course of RA - it
can be hypothesized that early remission will be associ-
ated with sustainability of remission. There currently are
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no studies that investigated the relationship between
time-to-remission and sustainability of remission. How-
ever, there are sufficient indications that in RA indeed
early response is predictive for later results [11-13].
Insight into the factors that determine sustained remis-
sion early in the disease course of RA is important to pro-
vide a better long-term outcome of patients with RA.
The main objective of this study was to study the asso-
ciation between time-to-remission and sustainability of
remission during the first three years of follow-up in a
cohort of patients with early RA, who were treated
according to daily practice. A second aim was to identify
independent predictors of time-to-remission and sustain-
ability or remission.
Materials and methods
Selection of patients
Eligible patients for this study were obtained from the
Nijmegen early RA inception cohort[14]. In this cohort
patients were included who were at least 18 years of age,
meeting the 1987 revised American College of Rheuma-
tology (ACR) classification criteria for RA, who had a dis-
ease duration less than one year and did not use
DMARDs before[15]. Patients were visiting the outpa-
tient clinic of the rheumatology departments of the Rad-
boud University Nijmegen or the Maartenskliniek in
Nijmegen, The Netherlands. In The Netherlands, nearly
all patients with RA are treated by rheumatologists work-
ing in hospitals.
All patients were regularly assessed in three-monthly
visits, but treatment decisions could be made at any time
according to the discretion of the treating rheumatolo-
gist. Patients were treated with conventional DMARDs
and/or biologicals and also glucocorticoids and non-ste-
roidal anti-inflammatory drugs (NSAIDs) could be used.
All clinical data on patient characteristics, medication
use, clinical and laboratory measures were prospectively
stored in an electronic database. All patients gave their
informed consent before inclusion in the inception
cohort, and the responsible local medical ethics commit-
tee had approved the study protocol. Inclusion and data
collection for this cohort are still ongoing.
Since we were interested in remission during three
years follow-up, all patients that were enrolled in the
inception cohort between 1 July 1986 and 31 December
2005 were selected for this study.
Clinical assessments
The following baseline patient variables were retrieved
from the database: age, gender, duration of RA, rheuma-
toid factor positivity, disease activity (disease activity
score (DAS)) and physical function (Health Assessment
Questionnaire, HAQ). Disease activity was assessed at
baseline and every three months thereafter by trained
research nurses, using tender and swollen joint counts,
erythrocyte sedimentation rate (ESR; mm/h) and patient
ratings. The DAS was calculated using a 44 joint count
for swelling (swollen joint count, SJC), a 53 joint count
graded for tenderness (tender joint count, TJC), counted
in 26 joint units (Ritchie Articular Index, RAI), general
health on a Visual Analogue Scale (VAS) of 100 mm, and
the value for ESR measured by the Westergren
method[16]. The DAS has not the same cut points as the
DAS28. A DAS ≥ 2.4 is regarded as low disease activity,
and a DAS >3.7 is regarded as high disease activity[17].
Other clinical variables assessed were: duration of
morning stiffness expressed in minutes, patient rating for
pain, patient's global assessment of disease activity and
physician's global assessment of disease activity all on a
VAS from 0-100, and C-reactive protein (CRP; mg/L).
Use of DMARDs, biologicals, and concomitant glucocor-
ticoids or NSAIDs was recorded during follow-up.
Remission definitions
Remission was defined according to a DAS < 1.6 (DAS
remission) and to modified ACR remission criteria
(mACR remission)[18]. Fulfillment of the mACR remis-
sion criteria required four of the following five criteria to
be met: 1) morning stiffness ≤ 15 minutes, 2) VAS pain ≤
10 mm, 3) no tender joints (out of 53 joints), 4) no swol-
len joints (out of 44 joints), and 5) ESR < 30 mm/h
(female) or < 20 mm/h (male)[18]. In comparison with
the original ACR remission criteria[19], fatigue was omit-
ted since this item was not assessed in the cohort. Since
there were three-monthly visits in our inception cohort,
duration of mACR remission had to be at least three
months, which differs from the duration of two months
as defined in the original ACR remission criteria[19].
Patients were regarded to be in sustained remission
when they maintained remission for six consecutive
months, which is three consecutive visits for DAS remis-
sion and two consecutive visits for mACR remission.
Statistical analysis
Time-to-remission was described using a Kaplan-Meier
curve. A Cox proportional hazard model with time-to-
remission as the dependent variable was used to calculate
the hazard for achieving remission within three years for
baseline variables. Variables univariately showing a sig-
nificance level of p < 0.05 were included into a multivari-
ate Cox model. The full multivariate model was reduced
by stepwise removal of baseline variables with a signifi-
cance level of p < 0.05.
For predicting sustained remission, a logistic regression
model with achieving sustained remission as dependent
variable was used to identify baseline predictors. The
same variable selection procedure was followed as
described above.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
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The relationship between time-to-remission and sus-
tainability of remission was analyzed using longitudinal
b i n a r y  r e g r e s s i o n  ( m i x e d  m o d e l s ) ,  c o r r e c t i n g  f o r
repeated measurements (autoregressive covariance struc-
ture) and using a logit link function for binary data.
Remission during three years was the dependent variable
with time-to-remission as the main covariate. The value
of the DAS in the previous visit was included in the
model. Other covariates were added to the model as con-
founders only if their addition leaded to a change of 10%
or more in the effect. In addition, the following interac-
tion terms were tested: gender with age, and calendar
time with time-to-remission. Besides the interaction term
with calendar time, also four sub-cohorts (inclusion
between 1985-1990, 1991-1995, 1996-2000, 2001-2005)
were defined, to analyze whether the relation between
time-to-remission and sustained remission changed over
calendar time.
For the relation between time-to-remission and sus-
tained remission, medical treatment was regarded as an
intermediate variable rather than a confounder. Treat-
ment was not considered as a confounder because both
time-to-remission and sustained remission are treatment
effects. Treatment obviously is in the causal pathway and,
therefore, it should not be treated as a confounder.
Instead, it was analyzed whether the relation between
time-to-remission and sustainability was different (effect
modification) for patients treated using DMARDs in
sequential monotherapy or as add-on therapy and also for
patients using MTX or SASP as first DMARD. For
descriptive purposes, treatment with DMARDs and glu-
cocorticoids was studied at baseline and during three
years for all sub-cohorts.
Regarding the three-year follow-up and definition of
sustained remission (six months or more) there might
have been patients who were not able to sustain their
remission since they attained remission after two and half
year. Therefore, a sensitivity analysis was performed with
only patients who achieved first remission before two and
half year and compared to using all patient.
In case of missing DAS values, the mean of the previous
and following scores was used (linear intrapolation) for
imputation. By means of sensitivity analysis, results of the
analysis using the dataset after imputation were com-
pared with the results using the dataset with missing val-
ues.
All analyses were performed separately for both DAS
and mACR remission as outcome. Statistical analyses
were carried out using SPSS version 16.0, statistical soft-
ware package (Chicago, IL, USA) and using PROC GEN-
MOD of SAS version 8.2 software (SAS Institute, Cary,
NC).
Results
Baseline characteristics
Complete datasets with assessments of disease activity
scores from baseline and a minimal follow-up of 140
weeks were available in 753 (86%) of the 873 included
early RA patients. Patients, who were not included in this
study, did not differ significantly or remarkably from
patients who were included with respect to age, gender,
rheumatoid factor positivity, disease duration, DAS,
HAQ, medication use and change in DAS between base-
line and six months (not shown).
Table 1 shows the baseline demographic and clinical
variables of all patients included. Nearly all patients were
included at moment of diagnosis as can be seen in the low
disease duration. The patients had on average a high level
of disease activity as shown by the mean DAS and the
joint counts, and a moderate level of disability a shown by
the HAQ.
Predictors for time-to-remission
From all n = 753 patients, n = 398 patients (53%) achieved
at least one visit in remission during the three years of
follow-up. The median time-to-remission was 33
months. Figure 1 shows a Kaplan-Meier time-to-event
curve of the time-to-remission for the four sub-cohorts of
calendar time. The curves indicate that the earliest sub-
cohort had median time-to-remission of 35 months, the
following two sub-cohorts had a median time of 36 and
28 months respectively, and the last sub-cohort had a
median time of 26 months to attain remission. Compari-
son of the early and late sub-cohorts revealed a signifi-
cantly difference in this time-to-remission (P < 0.01 by
overall log rank test).
Analyzing time-to-remission of only patients who
attained remission within three years, resulted into a
median time-to-remission of 14 months in the earliest
cohort and 10 months in the latter cohort.
In Table 2 it is shown which baseline variables are uni-
variately and multivariately predictive for time-to-remis-
sion. Univariate Cox-regression analyses showed a
significant difference between the sexes: male patients
reached remission sooner than female patients (18 and 36
months, respectively) (P < 0.0001). Baseline DAS was
strongly predictive for time-to-remission: patients with a
lower DAS at baseline achieved remission more rapidly
than those with a higher DAS at baseline (P < 0.0001). A
higher HAQ and higher age at disease onset were also
found to prolong the time-to-remission (P < 0.01). Fur-
ther, all individual components of DAS at baseline were
predictive for time-to-remission (P < 0.05). The interac-
tion between age and gender was not significant. In mul-
tivariate Cox-regression, only gender, age, and DAS were
independently predictive for time-to-remission.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
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Predictors for sustained remission
Of the 398 patients who ever attained remission, 142
(36%) patients had sustained remission with a median
time of being in remission of 19 months. Table 3 shows
the univariate and multivariate logistic regression analy-
ses to determine baseline predictors for reaching sus-
tained remission. Univariately, sustained remission was
predicted by a shorter time-to-remission, and lower DAS
and HAQ at baseline. Also, the tender joint count at base-
line was predictive for sustained remission. In multivari-
ate regression, none of the baseline variables were
independently associated with sustained remission,
except for time-to-remission. No significant interaction
terms were detected. Thus, time-to-remission emerged
as an important predictor of sustained remission.
Relationship between time-to-remission and sustained 
remission
Table 4 shows the descriptives of time-to-remission and
sustained remission and the relation between time-to-
remission and sustained remission. The median time
needed to reach remission was 12 months. The median
time that remission sustained was 19 months. The odds
ratio (OR) (95% CI) of the relation between time-to-
remission and having sustained remission was 1.11 (1.10-
1.12) (P < 0.0001). As time-to-remission was calculated in
months, this means that patients who achieved first
remission one month earlier, had a higher chance on sus-
tained remission, an OR of 1.11 than patients who
achieved first remission one month later. Achieving
remission three months earlier resulted in an OR of 1.37
to remain in remission. In case of one year earlier remis-
s i o n ,  t h i s  O R  e v e n  i n c r e a s e d  t o  3 . 5  t o  k e e p  s u s t a i n e d
remission. Accordingly, the chance on sustained remis-
sion increases with every month time-to-remission is
shorter. Illustratively, the median time-to-remission in
patients with sustained remission was 9 months (inter-
quartile range, IQR 4-13 months) while time-to-remis-
sion in patients with non-sustained remission was 13
months (IQR 7-24 months) (P < 0.0001). There were no
baseline variables (such as age and gender) that acted as
confounders, only the DAS value of the previous visit was
included as covariate in the model.
Sensitivity analyses with only patients who attained
remission before two and half year, resulted in an OR of
1.1. Also, using the dataset with missing values did not
alter the above OR.
Sustained remission during calendar time
The cohort was divided into four sub-cohorts according
to calendar time (Table 4). The number of patients who
achieved remission was comparable between the first and
the latter cohort. Sustained remission, on the other hand,
occurred more frequently in the latter cohort. Time-to-
remission was longer in the beginning of the cohort
(1985-1990) and also time in remission was less in the
early years of the cohort (Table 4). Despite these differ-
ences, the relationship between time-to-remission and
sustained remission remained constant over calendar
time as can be seen by the OR of each sub-cohort that
varied from 1.09 to 1.15 with great overlap of the four
confidence intervals.
mACR remission
Overall, mACR remission occurred less frequently than
DAS remission (Table 4). The independent predictors for
time-to-mACR remission were comparable with those
found for achieving DAS remission. Time-to-remission
for the four sub-cohorts is shown in Figure 2. Again, the
earlier sub-cohorts had a longer median time-to-remis-
sion than the last sub-cohort (P < 0.01). To sustain mACR
remission was also more difficult than DAS remission.
Time-to-remission was the strongest and single predictor
of sustained mACR remission. The relationship between
time-to-remission and sustained remission was again sig-
Table 1: Demographic and baseline disease characteristics 
of patients (n = 753)
Variable and range of values Patients 
included
Age (mean [SD], years) 54 [14]
Women (n [%]) 477 [63%]
Rheumatoid factor positive (n [%]) 578 [77%]
Disease duration (median [IQR], weeks) 0 [0-4]
DAS (mean [SD]) 3.98 [1.28]
DAS28 (mean [SD]) 5.07 [1.32]
HAQ score (median [IQR]) 0.63 [0.25-1.19]
ESR (median [IQR], mm/h) 29 [16-48]
CRP (median [IQR], mg/L) 12 [1.7-37]
44 swollen joint count (median [IQR]) 13 [8-18]
53 tender joint count (median [IQR]) 10 [5-17]
VAS pain, 0-100 (mean [SD], mm) 44 [23]
Patient's global assessment, 0-100 
(mean [SD], mm)
46 [24]
VAS GH, 0-100 (mean [SD], mm) 44 [22]
Physicians global assessment, 0-100 
(mean [SD], mm)
34 [18]
Morning stiffness (median [IQR], min) 30 [0-90]
DAS = disease activity score based on 53 tender joint counts 
(Ritchie Articular Index) and 44 swollen joint counts; DAS28 = 
disease activity score based on 28 tender and swollen joint 
counts; HAQ = health assessment questionnaire; ESR = 
erythrocyte sedimentation rate; CRP = C-reactive protein; VAS = 
visual analogue scale.IQR = interquartile range, P25-P75; SD = 
standard deviation.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
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nificant (OR = 1.15) and remained constant over calendar
time.
Medication use
Among the 753 patients included, 720 patients started
monotherapy (14% methotrexate (MTX), 67% sulphasala-
zine (SASP), 15% hydroxychloroquine and 4% other
DMARDs) and 33 patients received DMARDs combina-
tion therapy at baseline, mainly MTX combined with
SASP. During three years, 29% patient received a combi-
nation of DMARDs (mostly MTX plus SASP) as an add-
on strategy applied and 71% of the patients received a
sequential strategy of DMARDs. In the beginning of the
cohort, 5% of the patients were given combination ther-
apy, which increased to 39% in the last sub-cohort. Fur-
ther, in earlier cohorts SASP was in 54% the starting drug
compared to 24% in the latter cohorts. The use of MTX
increased from 1% to 16%. Biologicals were given to 17%
of the patients. Overall, 19% of the patients used predni-
sone and 49% received at least one intra-muscular/intra-
articular injection of prednisolone with a median of num-
ber of two (IQR 1-4).
With respect to patients who sustained their remission
(n = 142), nearly all (96%) patients started with mono-
therapy and SASP was described as first DMARD in 69%.
A higher proportion of patients received DMARDs in
sequential monotherapy until their first remission (87%)
compared to the whole patient group (71%) and a
DMARD add-on strategy was less commonly applied
(13% versus 29%). Also, the percentage of anti-TNF users
before first remission was actually low (3%). Further, 11%
of the patients received prednisone and 35% at leas one
intra-muscular/intra-articular injection of prednisolone
(median number of 1).
Remission and medication use
Since more patients started with SASP as first-line
DMARD, we investigated remission in both SASP and
MTX first-line patients. Whether treatment was started
with MTX or with SASP did not predict time-to-remis-
sion (p = 0.412), sustainability of remission (p = 0.091),
nor did it modify the relationship between time-to-
remission and sustainability of remission (p = 0.153). Fur-
ther, patients in sustained remission received more often
Figure 1 Time to achieve DAS-remission. Time to achieve DAS-remission within three years of follow-up in a cohort of early RA patients derived 
from the Nijmegen inception cohort (N = 753). Remission was defined according to the disease activity score (DAS) based on 53 tender joint counts 
and 44 swollen joint counts.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
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DMARDs in sequential monotherapy. Therefore, patients
were stratified according to treatment strategy: DMARD
sequential monotherapy (70%) or add-on therapy (30%).
The relation between time-to-remission and sustainabil-
ity was not different between both treatment groups (p =
0.609).
Discussion
This study was conducted to identify predictors for
achieving and sustaining remission and to investigate the
relationship between time-to-remission and sustained
remission according to two different remission criteria in
a cohort of early RA patients treated in daily practice
between 1985 and 2005. According to the results of this
study, the number of patients achieving remission was
comparable during the whole time frame of the cohort.
Predictors to achieve more rapidly DAS remission were
male gender, younger age and a low DAS or HAQ at base-
line. Sustained remission was only and mainly deter-
mined by time-to-remission; the chance of sustained
remission increased significantly with decreasing time-
to-remission. Over time, reflecting more intensive treat-
ment, the time-to-remission tended to shorten, the
occurrence of sustained remission tended to increase, but
the relation between time-to-remission and sustainability
remained fairly constant. This indicates that the relation
between time-to-remission and sustainability does not
heavily depend on the type or strategy of DMARDs given.
Results obtained with the mACR remission criteria were
similar.
This study is the first daily care study showing the influ-
ence of time-to-remission at sustained remission. In ear-
lier studies on evaluation of remission in daily practice,
comparable predictors have been identified for achieving
remission in patients with early RA [20,21]. Rheumatoid
factor [11,20] and anti-cyclic citrullinated peptide (anti-
CCP) antibody status [22], level of CRP[23] and presence
of erosions at baseline[20] have also shown to be predic-
tive for not achieving remission rapidly. Further, the early
start of DMARDs combination therapy[24] or anti-TNFα
agents plus MTX [5,7,8] in RA patients emerged to be
predictive for sustained remission.
Since treatment in patients with RA has shifted towards
a more early and aggressive treatment strategy, higher
remission rates and more sustainability of remission are
expected these days. Remarkably in this study, the associ-
ation between time-to-remission and sustained remission
was present in all cohort patients, irrespective of date of
inclusion. Therefore, early remission seems to be essen-
tial for sustained remission, and thus the further course
of RA. Earlier studies have already confirmed this impli-
cation. In addition, the frequency of remission after one
year was significantly higher among responders than
among the non-responders [11,25] and achieving low dis-
ease activity within three months of treatment was asso-
Table 2: Baseline predictors for time-to-DAS remission (n = 753)
Univariate1 Multivariate2
Variable Beta (β) P value HR (95%CI) Beta (β) P value HR (95%CI)
RF positive 0.114 0.328 1.121 (0.892-1.408)
Male gender -0.641 0.000 0.527 (0.433-0.641) -0.511 0.000 0.600 (0.469-0.767)
Age -0.009 0.008 0.991 (0.984-0.998) -0.007 0.047 0.993 (0.986-0.999)
Baseline DAS -0.364 0.000 0.695 (0.635-0.760) -0.693 0.000 0.500 (0.434-0.576)
Baseline HAQ -0.436 0.000 0.647 (0.529-0.791)
Dis duration -0.005 0.217 0.995 (0.987-1.003)
44 SJC -0.018 0.007 0.982 (0.969-0.995)
53 TJC -0.057 0.000 0.945 (0.932-0.958)
ESR -0.004 0.048 0.996 (0.992-0.999)
VAS GH -0.017 0.000 0.983 (0.978-0.987)
1 Results of univariate Cox proportional hazard models with baseline predictors for time-to-DAS remission (disease activity score, DAS<1.6) 
up to three years of follow-up, given with hazard ratios (HR) and 95% confidence intervals (95%CI). 2 Results of the final multivariate Cox 
proportional hazard prediction model with independent baseline predictors for the time-to-remission (disease activity score, DAS<1.6) up to 
three years of follow-up, given with hazard ratios (HR) and 95% confidence intervals (95%CI).
RF = rheumatoid factor; DAS = disease activity score based on 53 tender joint counts (TJC) and 44 swollen joint counts (SJC); HAQ = health 
assessment questionnaire; Dis = disease; ESR = erythrocyte sedimentation rate; VAS = visual analogue scale; GH = general health. Age was 
measured in years and disease duration in weeks.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
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ciated with low disease activity or remission at one
year[12].
Several criteria of (sustained) clinical remission are
available and remission results of studies may for this rea-
son depend on the remission criterion used [3,26]. This
study applied both DAS and mACR as remission criteria,
which resulted in similar predictors for attaining and sus-
taining remission. Moreover, the relationship between
time-to-remission and sustained remission remained sig-
nificant. Reaching and sustaining mACR remission was
only more difficult than DAS remission. Additionally, a
great proportion of patients (23%) who attained DAS
remission did not fulfill mACR remission. Since mACR
remission criteria include absence of both tender and
swollen joints, remission according to mACR is regarded
as very strict[27].
For the aim of this study, we used cohort data from the
Nijmegen inception cohort. Cohort data have the advan-
tage to be closely related to daily practice care[28] and,
therefore, the patients included in this study are supposed
to be representative of the general RA population attend-
ing outpatient clinics. Moreover, the inception cohort
from this study is regarded as a very valuable and com-
plete cohort since this cohort includes a long time span,
started from 1985 and still ongoing, and clinical variables
are systematically collected every three months.
However, a limitation of using data from daily practice
is that medication use differs for each patient and
changes over time. For that reason, medication use can-
not be analyzed as would it be an effect-modifier and
studying medical treatment may be complicated using
cohort data. Therefore, medication use in this study was
regarded as an intermediate variable and was described
for each sub-cohort to get more insight into time-trends
of medication. Further, we have demonstrated that
despite medication adjustments at the discretion of rheu-
matologists, the treatment strategy applied was mostly a
sequential or step-up strategy (with or without glucocor-
ticoids), starting with either MTX or SASP and the pre-
scription of anti-TNF agents was low.
The number of anti-TNF users in this study was low.
On the one hand the study includes the period 1990-2000
when anti-TNF was not available, on the other hand
because in the Netherlands, anti-TNF is used after failure
on at least two DMARDs. The results of this study, there-
fore, do not automatically generalize to patients treated
with anti-TNF. Leaving out the patients treated with anti-
TNF from the analysis did not change the results (not
shown). Further research should be necessary to investi-
gate, and even generalize, the relationship between time-
to-remission and sustained remission in patients using
(their first) anti-TNF treatment.
Table 3: Baseline predictors of sustained DAS remission (n = 753)
Univariate1 Multivariate2
Variable Beta (β) P value OR (95% CI) Beta (β) P value OR (95% CI)
Time-to-remis -0.091 0.000 0.913 (0.889-0.939) -0.094 0.000 0.910 (0.878-0.944)
RF positive 0.447 0.058 1.563 (0.985-2.481)
Male gender -0.379 0.067 0.685 (0.457-1.026)
Age 0.007 0.302 1.007 (0.993-1.022)
Baseline DAS -0.302 0.001 0.740 (0.620-0.882)
Baseline HAQ -0.567 0.011 0.567 (0.367-0.878)
Dis duration -0.003 0.745 0.997 (0.982-1.013)
44 SJC -0.012 0.384 0.988 (0.963-1.015)
53 TJC -0.070 0.000 0.932 (0.903-0.962)
ESR -0.004 0.349 0.996 (0.988-1.004)
VAS GH -0.009 0.075 0.991 (0.980-1.001)
1 Results of the univariate logistic regression model for sustaining remission (DAS<1.6 for at least 6 months or more) during 3 years of follow-
up and baseline variables, given with odds ratios (OR) and 95% confidence intervals (95%CI). 2 Results of the final multivariate logistic 
regression model for sustaining remission (DAS<1.6 for at least 6 months or more) during 3 years of follow-up and baseline variables, given 
with odds ratios (OR) and 95% confidence intervals (95% CI).
Remis = remission; RF = rheumatoid factor; DAS = disease activity score based on 53 tender joint counts (TJC) and 44 swollen joint counts 
(SJC); HAQ = health assessment questionnaire; Dis = disease; ESR = erythrocyte sedimentation rate; VAS = visual analogue scale; GH = general 
health. Time-to-remission was measured in months, age was measured in years and disease duration was measured in weeks.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
http://arthritis-research.com/content/12/3/R97
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Table 4: Relationship between time-to-remission and sustained remission
All patients 
(n = 753)
1985-1990
(n = 147)
1991-1995
(n = 158)
1996-2000
(n = 219)
2001-2005
(n = 229)
DAS remission
Achieving remission (n [%])1 398 [53%] 77 [52%] 68 [43%] 124 [57%] 129 [56%]
Time-to-remission
(median [IQR], months)
33
[11-36]
35
[14-36]
36
[12-36]
28
[9-36]
26
[9-36]
Sustained remission (n [%])2 142 [36%] 22 [29%] 25 [37%] 46 [37%] 49 [38%]
Time in sustained remission
(median [IQR], months])
19
[10-28]
9
[6-22]
22
[14-29]
18
[10-26]
22
[13-29]
Relationship between time to
achieve and sustained 
remission
(OR [95%CI])3
1.11
[1.10-1.12]
1.09
[1.07-1.11]
1.15
[1.12-1.17]
1.09
[1.08-1.11]
1.13
[1.11-1.15]
mACR remission
Achieving remission (n [%])4 226 [30%] 48 [33%] 45 [29%] 62 [28%] 71 [31%]
Time-to-remission
(median [IQR], months)
13
[8-24]
15
[10-28]
13
[7-24]
15
[9-23]
10
[7-19]
Sustained remission (n [%])5 58 [26%] 8 [17%] 18 [33%] 13 [21%] 19 [27%]
Time in sustained remission
(median [IQR], months])
10
[6-16]
7
[6-8]
11
[7-16]
7
[6-16]
13
[7-24]
Relationship between time to
achieve and sustained 
remission
(OR [95%CI])3
1.15
[1.14-1.16]
1.13
[1.09-1.16]
1.12
[1.07-1.18]
1.08
[0.96-1.22]
1.12
[0.93-1.16]
1 Number of patients achieving at least one period of remission (disease activity score, DAS<1.6) during 3 years follow-up. 2 Number of 
patients who had sustained DAS remission (6 months or more) during 3 years follow-up. 3 Odds ratios (ORs) of remission during 3 years follow-
up analyzed by longitudinal binary regression with remission status over time as dependent variable, time-to-remission (months) and DAS 
value of the previous visit as main covariates. 4 Number of patients achieving at least one period of remission (modified American College of 
Rheumatology, mACR) during 3 years follow-up. Fulfillment of the mACR remission criteria was based on 4 of the following 5 criteria to be 
met: 1) morning stiffness ≤ 15 minutes, 2) VAS pain ≤ 10 mm, 3) no tender joints (out of 53 joints), 4) no swollen joints (out of 44 joints), and 
5) ESR < 30 mm/h (female) or < 20 mm/h (male). 5 Number of patients who had sustained mACR remission (6 months or more) during 3 years 
follow-up. IQR = interquartile range, P25-P75; CI = confidence interval.
In some patients, joint damage may proceed despite
clinical remission [29,30], However, low levels of inflam-
mation and specifically remission are associated with less
(further) progression of joint damage [31,32]. Clinical
remission and ultimately the halt of progression of joint
damage is regarded as the current treatment goal in
RA[1]. In clinical trials, remission has already shown to
be attainable [7,33,34] and striving for a sustained state of
(drug-free) remission has become the ultimate aim in
RA[35]. However, the rate of achieving and sustaining
(mACR) remission in daily practice is still very low. The
results of this study have shown that within three years,
53% and 30% of the patients achieved at least one visit in
DAS or mACR remission, which are comparable (or even
higher) to those found in other daily care studies
[2,5,9,11,18,36]. A state of sustained clinical remission
was in this study difficult to reach (23-36%), which was
also demonstrated in previous studies [11,37].
Despite the relatively low percentage of sustained
remission, there are arguments to believe that substantial
increases in sustained remission rates are these days
expected. Additionally, treatment strategies with conven-
tional DMARDs can be improved considerably by apply-
ing tight control of disease activity, including a
medication protocol with regular assessments of disease
activity and a threshold (remission) to determine whether
treatment has to be changed [9,34,38,39]. Moreover, in
clinical trials the early introduction of DMARDs in com-
bination with prednisone or anti-TNF, applied as a 'step-
down' strategy [5,6], has shown to be very effective. How-
ever, in daily practice this is not a common treatment
strategy. Therefore, starting anti-TNF therapy more rap-
idly, in DMARDs failures and patients with poor progno-
sis at baseline in particular, may be necessary for
achieving higher remission rates.Schipper et al. Arthritis Research & Therapy 2010, 12:R97
http://arthritis-research.com/content/12/3/R97
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Conclusions
In conclusion, the results of this study show that attaining
first remission sooner, chance of sustained remission is
becoming significantly higher. This relationship between
time-to-remission and sustained remission remained
constant over the whole cohort period from 1985 to 2005.
The fact that time-to-remission is the strongest predictor
for sustained remission supports the fact that aiming for
remission as soon as possible is the treatment goal in
patients with early RA. Aiming for remission will be bet-
ter achievable with treatment strategies applied as tight
control. By measuring disease activity and targeting a low
value in the measure (remission) we use, remission is
achievable and even sustained remission. Tight control
may be applied with any DMARD and all DMARDs may
be needed to get remission, For many patients with RA,
MTX alone, or in combination with corticosteroids, will
give the desired state of sustained remission.
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